Exploring molecular mechanisms of anti-platelet adhesion of Chinese medicine for promoting blood circulation and removing blood stasis by activity screen and network analysis
10.16438/j.0513-4870.2019-0297
- VernacularTitle:活性筛选和网络分析初步阐释常用活血化瘀中药抗血小板黏附的分子机制
- Author:
Shan LI
1
;
Ming LÜ
2
;
Jian YANG
1
;
Xing-ru BAO
3
;
Guang-xu XIAO
1
;
Yan ZHU
1
Author Information
1. Tianjin Modern Medicine Key Laboratory of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China; Tianjin International Biomedical Research Institute, Chinese Medicine New Drug Research and Development Center, Tianjin 300457, China
2. Tianjin Modern Medicine Key Laboratory of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China; Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; Tianjin International Biomedical Research Institute, Chinese Medicine New Drug Research and Development Center, Tianjin 300457, China
3. Tianjin Modern Medicine Key Laboratory of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
- Publication Type:Research Article
- Keywords:
platelet adhesion;
Chinese medicine for promoting blood circulation and removing blood stasis;
activity screening;
network analysis;
Danshen-Chuanxiong
- From:
Acta Pharmaceutica Sinica
2019;54(11):1990-1999
- CountryChina
- Language:Chinese
-
Abstract:
Platelet adhesion is a key process in thrombosis. Anti-platelet adhesion effect of some Chinese medicines for promoting blood circulation and removing blood stasis (PBCRBS) has been reported, but their relative efficacies as a whole and specific targets remained unclear. This paper combined activity screening, drug compatibility analysis, pathway clustering, target prediction, and molecular docking to explore the mechanism of anti-platelet adhesion by PBCRBS Chinese medicine. Screening the activity of anti-platelet adhesion of 58 commercially available PBCRBS Chinese patent medicines showed that about 50.0% significantly inhibit ADP-induced platelet adhesion in vitro, and about 96.6% significantly inhibit thrombin-induced platelet adhesion in vitro. The animal experiment involved was approved by the Animal Ethics Committee of Tianjin International Biomedical Research Institute. Combined with the auxiliary platform for TCM (V2.0) inheritance showed that the compatibility of Danshen-Chuanxiong was used most frequently among the top 20 active proprietary Chinese patent medicines. IPA network analysis revealed that IL-1, APP and CCL2 might be the key targets for anti-platelet adhesion function of Danshen-Chuanxiong against atherosclerosis, neuroinflammation and chemokine signaling pathways as the main mechanisms. Molecular docking analysis confirmed the interaction between one of the active compounds shared by Danshen and Chuanxiong, i.e. chlorogenic acid, with its target CCL2. This study provides TCM theory guidance and experimental support for targeting platelet adhesion in anti-thrombosis therapy by Chinese medicine for promoting blood circulation and removing blood stasis.
